Business Context and Reporting Period
Company: Moleculin Biotech, Inc. (MBRX)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: Moleculin is a clinical-stage pharmaceutical company focused on developing Annamycin (naxtarubicin), a next-generation anthracycline, for the treatment of relapsed/refractory acute myeloid leukemia (R/R AML). The company is currently conducting the pivotal Phase 2/3 "MIRACLE" trial. It also maintains portfolios for WP1066 (immune modulators) and WP1122 (glycolysis inhibitors). The company has no revenue-generating operations and relies on financing to fund development.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2026 |
Six Months Ended June 30, 2026 |
Six Months Ended June 30, 2025 |
|---|---|---|---|
| Revenues | $0 | $0 | $0 |
| Net Loss | $(7,635) | $(20,480) | $(23,713) |
| Net Loss per Share (Basic/Diluted) | $(1.40) | $(4.60) | $(47.61) |
| Operating Expenses | $7,561 | $15,435 | $11,663 |
| Cash and Cash Equivalents (End of Period) | $7,262 | $7,262 | $7,557 |
| Net Cash Used in Operating Activities | N/A | $(12,768) | $(10,146) |
| Net Cash Provided by Financing Activities | N/A | $11,225 | $13,422 |
| Total Assets | $21,087 | $21,087 | $22,126 (Dec 31, 2025) |
| Total Liabilities | $9,500 | $9,500 | $7,120 (Dec 31, 2025) |
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses increased by $3.8 million (32%) for the six months ended June 30, 2026, compared to the prior year period. This was primarily driven by a $2.7 million increase in costs related to the MIRACLE clinical trial and $0.7 million in additional nonclinical studies.
- Net Loss: Net loss decreased by $3.2 million for the six-month period compared to 2025. This improvement was largely due to a $10.8 million gain from the change in fair value of warrant liabilities in 2026, contrasting with a $0.6 million loss in the same period in 2025.
- Warrant Activity: Significant warrant inducement and exercise activity occurred in Q1 2026, resulting in gross proceeds of approximately $8.3 million from the exercise of Series E and F warrants and the issuance of Series H warrants. This activity also triggered anti-dilution adjustments and deemed dividends.
- Reverse Stock Split: A 1-for-25 reverse stock split was effected on December 1, 2025. All share and per-share data in the filing have been retroactively adjusted to reflect this split.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Clinical Progress: The company released interim unblinded data for the first 45 subjects of the MIRACLE trial (Part A) on June 30, 2026. Annamycin arms demonstrated complete remission (CR) rates of 43% and 36% compared to 12% for the control arm. Full unblinding of Part A (90 subjects) is expected between December 2026 and February 2027.
- Liquidity: As of June 30, 2026, the company had $7.3 million in cash. Management anticipates this is insufficient to fund operations for at least one year. However, a subsequent public offering completed on August 3, 2026, raised approximately $9.3 million in gross proceeds. Management believes combined funds will support operations into the first quarter of 2027, though an additional ~$8 million is needed to reach the second quarter of 2027.
- Subsequent Financing: On August 3, 2026, the company completed an offering of common stock/pre-funded warrants and Series I Warrants. This offering triggered anti-dilution adjustments to the exercise prices of outstanding Series G and H warrants.
Risks and Contingencies
- Going Concern: The filing includes a substantial doubt disclosure regarding the company's ability to continue as a going concern without additional financing.
- Nasdaq Compliance: The company is not in compliance with Nasdaq's minimum bid price requirement ($1.00). Since a reverse stock split occurred within the last year, the company is not eligible for a standard grace period and faces potential delisting if compliance is not regained.
- Warrant Dilution: Future financing at prices below the exercise price of Series I warrants (issued in August 2026) will trigger downward adjustments to the exercise price, subject to a $0.21 floor, potentially causing significant dilution.
Investor Verification Checklist
- Cash Runway: Verify the exact timeline of cash burn post-August 2026 financing and the specific milestones required to raise the additional ~$8 million needed for Q2 2027.
- Nasdaq Status: Monitor the company's stock price and any filings regarding a plan to regain compliance with Nasdaq listing standards to avoid delisting.
- Warrant Liability: Review the impact of the August 2026 offering on the exercise prices of existing warrants (Series G and H) and the potential for further dilution in future capital raises.
- Clinical Data: Await the full unblinded data release for the MIRACLE trial Part A (expected Dec 2026-Feb 2027) to validate the interim efficacy claims.
- Accounting Policy Change: Note the retrospective change in accounting policy regarding warrant classification (liability to equity) which significantly altered historical net loss figures.